Sanofi: Filing of the 2016 U.S. Form 20-F and French "Document de Référence" containing the Annual Financial Report

(Thomson Reuters ONE) -


Filing of the 2016 U.S. Form 20-F and French "Document de Référence" containing
the Annual Financial Report


Paris, France - March 3, 2017 - Sanofi announces today the filing of its Form
20-F with the U.S. Securities and Exchange Commission (SEC) and its "Document de
Référence" containing its Annual Financial Report with the French market
regulator Autorité des marchés financiers (AMF).

These documents are available on the "Investors" page of the company's corporate
website (www.sanofi.com), under the heading "Regulated Information in France".
In addition, the Form 20-F is available on the website of the SEC (www.sec.gov)
and the "Document de Référence" is available on the website of the AMF (www.amf-
france.org). A hard copy of these documents, each of which contains our complete
audited financial statements, may be received free of charge, upon request.

About Sanofi
Sanofi, a global healthcare leader, discovers, develops and distributes
therapeutic solutions focused on patients' needs. Sanofi is organized into five
global business units: Diabetes and Cardiovascular, General Medicines and
Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Consumer Healthcare. Sanofi
is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

--------------------------------------------------------------------------------

Contacts:

Media Relations Investor Relations
Laurence Bollack George Grofik
Tel: + (33) 1 53 77 46 46 Tel.: + (33) 1 53 77 45 45
mr(at)sanofi.com ir(at)sanofi.com



Press release (PDF):
http://hugin.info/152918/R/2084844/786006.pdf



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Sanofi via GlobeNewswire

Weitere Infos zu dieser Pressemeldung:
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
Datum: 03.03.2017 - 19:14 Uhr
Sprache: Deutsch
News-ID 528051
Anzahl Zeichen: 2300

contact information:
Town:

PARIS

Kategorie:

Business News

Diese Pressemitteilung wurde bisher 331 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Sanofi: Filing of the 2016 U.S. Form 20-F and French "Document de Référence" containing the Annual Financial Report"
steht unter der journalistisch-redaktionellen Verantwortung von

Sanofi (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

New Epidemiological Data Provide Additional Safety Evidence for Lantus(R) ...

PARIS, FRANCE -- (Marketwire) -- 06/11/12 -- Sanofi (EURONEXT PARIS: SAN) (NYSE: SNY) today announced new results of a large-scale epidemiological program, conducted by independent researchers in the northern European countries, at Kaiser Permanent ...

Sanofi Announces Results of ORIGIN, the World's Longest and Largest Randomi ...

PARIS, FRANCE -- (Marketwire) -- 06/11/12 -- Sanofi (EURONEXT: SAN) (NYSE: SNY) announced today results from the landmark ORIGIN trial (Outcome Reduction with Initial Glargine Intervention), which showed that Lantus® (insulin glargine [rDNA] injec ...

Lyxumia(R) (lixisenatide) in Combination With Basal Insulin Plus Oral Anti-Diabe ...

PARIS, FRANCE -- (Marketwire) -- 06/09/12 -- Sanofi (EURONEXT: SAN) (NYSE: SNY) announced today data demonstrating Lyxumia®* (lixisenatide), a once-daily investigational GLP-1 agonist, in combination with basal insulin plus oral anti-diabetic agen ...

Alle Meldungen von Sanofi